Pfizer And Moderna Reap Rewards Of Expanded US And EU Deals
Hundreds Of Millions More Doses Purchased
The two rival mRNA vaccines are proving attractive in the face of new variants, and could dominate once SARS-CoV2 enters the ‘endemic’ stage.
The two rival mRNA vaccines are proving attractive in the face of new variants, and could dominate once SARS-CoV2 enters the ‘endemic’ stage.